Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
The generic injectables market was valued at USD 61.34 Billion in 2025. It is poised to grow at a CAGR of 7.80% during the forecast period of 2026-2035, and reach USD 130.00 Billion by 2035. The market growth is driven by the rising prevalence of chronic diseases, increasing demand for cost-effective therapies, expanding hospital usage, and growing adoption of sterile injectable generics globally.
Base Year
Historical Period
Forecast Period
In January 2026, Fresenius Kabi launched a new ustekinumab biosimilar format, strengthening prefilled syringe offerings and improving treatment flexibility globally.
In March 2025, Fresenius Kabi gained FDA approval for denosumab biosimilars, expanding sterile injectables and improving access globally.
In December 2025, Amneal Pharmaceuticals and mAbxience received FDA approval for Boncresa™ and Oziltus™, expanding biosimilar injectable options and improving treatment accessibility globally.
Compound Annual Growth Rate
7.8%
Value in USD Billion
2026-2035
*this image is indicative*
The market is witnessing steady growth driven by rising demand for cost-effective therapies, increasing chronic disease burden, and expanding hospital-based treatments. Regulatory support and streamlined pathways such as ANDA approval are encouraging market entry. Additionally, growing incidences of drug shortages and emphasis on quality manufacturing are further supporting the adoption of generic injectable products globally. The market reached a value of approximately USD 61.34 Billion in 2025.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Rising Biosimilar Approvals to Drive the Market Demand
Increasing drug shortages and rising demand for affordable therapies are major market drivers. For instance, in March 2025, Fresenius Kabi received U.S. FDA approval for denosumab biosimilars, expanding its sterile injectable portfolio. This approval is expected to strengthen supply availability, reduce treatment costs, and support broader patient access during the forecast period.
Key trends shaping the market include increasing adoption of complex injectables, rising biosimilar development, growing hospital demand, technological advancements in delivery systems, and expanding regulatory approvals supporting global market penetration.
Increasing Adoption of Advanced Delivery Systems to Support Market Expansion
Growing chronic disease burden and increasing adoption of advanced delivery formats are influencing trends. For instance, in January 2026, Fresenius Kabi introduced a new presentation of its ustekinumab biosimilar, strengthening its prefilled syringe and injectable portfolio. This development is likely to enhance treatment flexibility and improve patient access across global healthcare systems during the forecast period.
Market Breakup by Product Type
Market Breakup by Container Type
Market Breakup by Application
Market Breakup by Route of Administration
Market Breakup by Distribution Channel
Market Breakup by Region
Oncology Likely to Lead the Market Segment by Application
Oncology by application, accounted for more than 33% of the market share during the historical period, driven by the rising global cancer burden and increasing reliance on cost-effective treatment options. The growing use of sterile injectable therapies in hospital settings continues to support segment dominance, ensuring efficient drug delivery and improved patient outcomes across diverse oncology indications worldwide.
North America captured above 36% of the revenue share during the historical period, supported by strong healthcare infrastructure and high adoption of generics. Favorable regulatory frameworks and increasing availability of biosimilar injectable products have further strengthened regional growth, enabling cost-effective treatment access while supporting innovation and competitive dynamics across the pharmaceutical landscape.
The key features of the market report comprise patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Pfizer Inc., headquartered in New York, United States, and founded in 1849, is a global pharmaceutical leader. Its generic injectables portfolio includes anti-infectives, oncology, and hospital-based therapies, with strong capabilities in sterile injectable manufacturing.
Teva Pharmaceutical Industries Ltd., headquartered in Tel Aviv, Israel, and established in 1901, is a leading generics manufacturer. Its portfolio includes a wide range of hospital injectables and biosimilars, supporting complex generic development. The company continues to expand its injectable pipeline to address growing demand for cost-effective therapies worldwide.
Baxter, headquartered in Deerfield, Illinois, and founded in 1931, specializes in hospital-focused therapies. Its portfolio includes IV solutions, anesthesia, and injectable generics, with strong expertise in prefilled syringe systems. Baxter remains a key player in sterile manufacturing, supporting hospitals with essential injectable medicines and delivery technologies globally.
Novartis Pharmaceuticals Corporation, headquartered in Basel, Switzerland, and founded in 1996, operates through its Sandoz division in generics. Its injectable portfolio includes biosimilars and oncology therapies, strengthening presence in biosimilar injectable segments. The company continues expanding global access to affordable injectables through innovation and regulatory approvals.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market are Fresenius SE & Co. KGaA, Endo, Inc., Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd., Sagent Pharmaceuticals, Viatris Inc., Biocon, Sanofi, Lupin, Aurobindo Pharma Limited, and Sun Pharmaceutical Industries Ltd, among others.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product Type |
|
| Breakup by Container Type |
|
| Breakup by Application |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share